Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)
Bullboard Posts
User Avatar Image
(325)
•••
Post by Actuarialon Mar 26, 2018 3:12pm
95 Views
Post# 27783585

sizeable market + P-value <0.001 => ATE-346 blockbuster drug

sizeable market + P-value <0.001 => ATE-346 blockbuster drug1. There is no doubt that NSAID is a $11B market. 2. When P-value is <0.05, it="" is="" called="" statistical="" significant.="" for="" ate-346,="" p-value=""><0.001 means there is only 0.1% chance that 250mg ate-346 be no better than naproxen 2x500mg. there is very little chance for ate-346 to fail in later phase iib efficacy trial or phase iii. most drugs passed phase ii but failed to pass phase iii due to its p-value too close to 0.05 at phase ii. ate-346 is almost a sure bet to be a blockbuster drug. means="" there="" is="" only="" 0.1%="" chance="" that="" 250mg="" ate-346="" be="" no="" better="" than="" naproxen="" 2x500mg.="" there="" is="" very="" little="" chance="" for="" ate-346="" to="" fail="" in="" later="" phase="" iib="" efficacy="" trial="" or="" phase="" iii.="" most="" drugs="" passed="" phase="" ii="" but="" failed="" to="" pass="" phase="" iii="" due="" to="" its="" p-value="" too="" close="" to="" 0.05="" at="" phase="" ii.="" ate-346="" is="" almost="" a="" sure="" bet="" to="" be="" a="" blockbuster="">
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities